Ypsomed goes direct in India
This article was originally published in Clinica
Executive Summary
Swiss pen injector manufacturer Ypsomed is opening a subsidiary in India to capitalise on the rapidly rising number of diabetics in the country. According to the Burgdorf company, the Indian insulin market is expected to grow from SwFr88m ($78.7m) in 2005 to SwFr121m in 2010. While 85% of insulin is currently injected with normal syringes, sales of pen injector systems in India is growing at 35% each year, said Ypsomed. The company already has a presence in Asia, with distributors in Singapore, Malaysia and Iran.